WNK2 and melanoma: These two most common and mutually exclusive activating mutations of BRAFV600E and NRASQ61K have been primarily documented in more than 60% of human melanomas, leading to the constitutive signaling of the mitogen-activated protein kinase (MAPK) pathway [12, 15–17], as shown in Figure 3.